Related Experiment Videos
Rectal cancer: integrating oxaliplatin into chemoradiation studies
1Gastrointestinal Cancer Center, Massachusetts General Hospital Cancer Center, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA. dpryan@partners.org
Oncology (Williston Park, N.Y.)
|February 24, 2001
Summary
This study evaluates oxaliplatin in preoperative combined-modality treatment for advanced rectal cancer. It explores its potential to improve outcomes for T3 and T4 stages.
Area of Science:
- Oncology
- Clinical Trials
- Gastrointestinal Cancer Research
Background:
- Standard care for T3 rectal cancer involves adjuvant chemoradiation with fluorouracil (5-FU).
- Preoperative therapy is an option for T3 and standard for T4 rectal cancer.
- Oxaliplatin shows promise in reducing systemic disease and radiosensitizing tumors.
Purpose of the Study:
- To evaluate oxaliplatin in preoperative combined-modality regimens for locally advanced rectal cancer.
- To assess the safety and potential efficacy of this novel treatment approach.
Main Methods:
- Phase I/II study (CALGB 89901) for T4 rectal cancer.
- Phase I study (ECOG E-1297) for locally advanced T3 or T4 rectal cancer.
- Investigating preoperative combined-modality treatment including oxaliplatin.
Main Results:
- Data on specific outcomes (response rates, toxicity, survival) are not yet available in the abstract.
- The abstract focuses on the rationale and design of the ongoing studies.
Conclusions:
- Ongoing studies are evaluating oxaliplatin as part of preoperative combined-modality therapy for advanced rectal cancer.
- Further research is needed to determine the role of oxaliplatin in rectal cancer treatment.